ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
advertisementadvertisement
Clinica Chimica Acta
Volume 357, Issue 2, 24 July 2005, Pages 202-209
Clinical Proteomics: Translation of New Insights into Clinical Practice - International Conference on Laboratory Medicine, Padua, Italy, 29 October 2004 - International Conference on Laboratory Medicine
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (279 K)

 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.cccn.2005.03.028    How to Cite or Link Using DOI (Opens New Window)
Copyright © 2005 Elsevier B.V. All rights reserved.

A proteomic approach in the study of an animal model of Parkinson's disease

Angela De Iuliisa, Corresponding Author Contact Information, E-mail The Corresponding Author, Jessica Grigolettoa, Alessandra Recchiab, Pietro Giustib and Paola Arslana

aDepartment of Diagnostic Sciences and Special Therapies, University of Padua, Viale G. Colombo 3, 35121 Padua, Italy bDepartment of Farmacology and Anaestesiology “E. Meneghetti” University of Padua, Padua, Italy

Received 4 March 2005; 
accepted 9 March 2005. 
Available online 8 June 2005.

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Abstract

Background

The aetiology of Parkinson's disease (PD), an age-related disorder characterized by a progressive degeneration of dopaminergic neurons of the substantia nigra (SN) pars compacta, remains unclear. Current treatments, such as administration of L-DOPA, are only symptomatic and do not stop or delay the progressive loss of neurons. In fact, it has been suggested that the dopamine precursor L-DOPA, increases generation of reactive oxygen species (ROS) leading to further neuronal damage.

A similar loss in nigrostriatal dopaminergic neurons is produced on intracerebral administration of the catecholaminergic neurotoxin 6-hydroxydopamine (6-OHDA). In an animal model of PD, termed ‘the hemiparkinsonian rat’, unilateral injection of 6-OHDA into the nigrostriatal pathway results in extensive loss of dopaminergic cells in the ipsolateral SN.

In an attempt to identify some of the proteins that are involved in dopaminergic neuronal death, we used the proteomic methods to analyze this animal model of PD.

Methods

Five hemiparkinsonian rats were obtained by intranigral stereotaxic injection of 6-OHDA.The right 6-OHDA-lesioned substantia nigra and striatum tissues along with the left, unlesioned controlateral tissues, were excised and homogenized, using urea-based buffer, to extract the tissues protein.

The separation of the protein mixtures and the visualization of the protein patterns obtained were performed using two-dimensional polyacrylamide gel electrophoresis (2D-PAGE).

Protein profiles of control and treated tissues were compare by the PDQuest 2D-gel analysis software (BIO-Rad laboratory). The protein spots showing differential expression were analysed by matrix assisted laser desorption/ionizing time of flight (MALDI-TOF) mass spectrometry.

Results

The brain protein extraction and solubilization protocol was validated obtaining a satisfactory protein profile. In comparison to the normal rats, hemiparkinsonian animals exhibited a different expression in α-enolase and β-actin in substantia nigra and striatum, respectively.

Conclusion

The proteomic study of 6-OHDA-induced lesions in the nigrostriatial pathway allowed us to identify two proteins, α-enolase and β-actin, showing increased levels in the 6-OHDA-lesioned brain tissues compared to control. Previous studies described the same proteins as oxidized and proteins in Alzheimer's disease (AD) brain. Our preliminary data could mirror those results pointing out a common mechanism of neurodegenerative diseases.

Keywords: Parkinson's disease; Neurodegenerative mechanism; Protein oxidation; Proteomics

Article Outline

1. Introduction
2. Results and discussion
References




Clinica Chimica Acta
Volume 357, Issue 2, 24 July 2005, Pages 202-209
Clinical Proteomics: Translation of New Insights into Clinical Practice - International Conference on Laboratory Medicine, Padua, Italy, 29 October 2004 - International Conference on Laboratory Medicine
 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.